SNPing Away at Cancer.

A delicate balance in the levels of proteins that regulate the p53 tumor suppressor pathway exists such that subtle changes alter p53 tumor suppressor activity and cancer risk. Many single-nucleotide polymorphisms (SNPs) in the p53 pathway alter p53 transcriptional activity and are associated with cancer risk. In addition, some SNPs influence the gain-of-function (GOF) activities of mutant p53 through unknown mechanisms.

View Article and Find Full Text PDF

Similar Publications

SNPing away to individualize induction therapy for acute myelogenous leukemia.

Leuk Lymphoma

August 2016

a Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology , Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, Chicago , IL , USA ;

Jason B Kaplan Jessica K Altman Leonidas C Platanias

View Article and Find Full Text PDF

Similar Publications

SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.

Pharmacol Ther

January 2013

Department of Therapeutic Radiology, Yale School of Medicine, 15 York Street, Hunter Building, HRT-205, New Haven, CT 06510, USA.

David W Salzman Joanne B Weidhaas

MicroRNAs are master regulators of gene expression and control many biological pathways such as cell growth, differentiation and apoptosis. Deregulation of microRNA expression and activity results in a myriad of diseases including cancer. Recently, several reports have indicated that single nucleotide polymorphisms (SNPs) in microRNAs and microRNA-target sites impact microRNA biology and associate with cancer risk, treatment response and outcome.

View Article and Find Full Text PDF

Similar Publications